Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orphan Europe, a Recordati group company, has submitted an original new drug application for Carbaglu to the FDA.
Subscribe to our email newsletter
The new drug application (NDA) provides for the safe and effective use of Carbaglu in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the deficiency of the liver enzyme N-acetylglutamate synthase.